Zepbound is a prescription medication containing tirzepatide. It is approved by the U.S. Food and Drug Administration for certain adults with obesity or overweight accompanied by at least one weight-related health condition, when used alongside a reduced-calorie diet and increased physical activity. Zepbound is also approved for treatment of moderate-to-severe obstructive sleep apnea in adults with obesity.
Zepbound is the brand name for tirzepatide, a medication administered by subcutaneous injection.
The FDA originally approved Zepbound for chronic weight management in adults with obesity or adults with overweight who also have at least one weight-related medical condition. In December 2024, the FDA approved Zepbound for adults with moderate-to-severe obstructive sleep apnea and obesity.
Zepbound works by activating two hormone receptors called GIP and GLP-1. These hormones are involved in appetite regulation, food intake, and glucose metabolism.
The medication is available in several dosage strengths, allowing treatment to be increased gradually under medical supervision.
Zepbound is a prescription medication. A prescription from an appropriately licensed healthcare professional is required before a pharmacy can dispense it.
Zepbound is available in several strengths.
The current U.S. injection strengths are:
Treatment generally begins at the 2.5 mg dosage. The FDA prescribing information identifies this as the starting dosage rather than a maintenance dosage.
After the initial treatment period, the dose may be increased according to the prescribing information and individual medical circumstances.
Maintenance doses for weight management can include 5 mg, 10 mg, or 15 mg once weekly. For obstructive sleep apnea, recommended maintenance dosages include 10 mg or 15 mg once weekly.
Dose changes should only occur according to instructions from the prescribing healthcare professional.
A CVS Pharmacy location can dispense Zepbound when a valid prescription has been received and the medication is available through the pharmacy's supply channels.
A prescription can generally be sent electronically by a healthcare provider to the selected CVS Pharmacy.
Once the prescription reaches the pharmacy, the pharmacy processes the order through its normal prescription system.
The final amount charged depends on the patient's insurance or payment method.
Prescription processing can involve several steps, including insurance verification, prior authorization requirements, inventory checks, and payment processing.
Self-pay means paying for a prescription without submitting the medication cost to an insurance plan.
For Zepbound, self-pay can be relevant when:
Self-pay does not necessarily mean that every pharmacy charges the same amount.
Cash prices can vary according to dosage, pharmacy, purchasing arrangements, and applicable programs.
Zepbound pricing has changed over time as manufacturer programs and direct-pay arrangements have expanded.
Eli Lilly, the manufacturer of Zepbound, has introduced self-pay programs through LillyDirect and related pharmacy arrangements.
The manufacturer has also announced changes to cash pricing for certain Zepbound single-dose vial strengths.
Because self-pay prices can change, a price displayed by a manufacturer or pharmacy should be checked for the specific dosage and purchasing method.
A quoted price should not automatically be treated as the amount charged at every CVS location.
Insurance pricing and cash pricing are also different.
A prescription processed through insurance can have a copay, deductible, coinsurance, or other patient responsibility. A self-pay prescription is instead charged at the applicable cash rate or program price.
CVS does not publish one universal nationwide self-pay price for Zepbound that applies to every prescription and every location.
The amount can vary according to the medication strength and the applicable purchasing arrangement.
A CVS pharmacy can provide the current cash price for a specific prescription.
Price comparison services may also display estimated retail prices, but those figures should not be assumed to represent the final amount charged at a particular CVS location.
The most reliable comparison involves checking the exact strength, package type, quantity, insurance status, and applicable savings program.
Eli Lilly has established savings programs for certain commercially insured patients and separate self-pay arrangements.
Eligibility depends on factors such as insurance type, prescription indication, enrollment requirements, and program terms.
Government insurance programs such as Medicare and Medicaid have different rules from commercial insurance.
A manufacturer savings card should not be assumed to apply to every patient.
Program terms can also change.
For this reason, current eligibility requirements should be checked through the manufacturer's official program information before relying on a particular advertised price.
Insurance coverage for Zepbound varies significantly.
Some commercial insurance plans cover Zepbound for specific indications, while others exclude weight-loss medications.
Coverage can also depend on whether the medication is prescribed for chronic weight management or obstructive sleep apnea.
A health plan may require prior authorization before approving the prescription.
Prior authorization means the insurance company requires additional information from the healthcare provider before determining whether the medication qualifies for coverage.
Some plans can also require step therapy, meaning other treatments must be tried before Zepbound is covered.
Medicare coverage for Zepbound depends on the medical indication and applicable federal rules.
Historically, Medicare Part D generally excluded medications prescribed solely for weight loss. However, changes to federal policy and new FDA indications have affected the circumstances under which certain medications may receive Medicare coverage.
Zepbound's approval for moderate-to-severe obstructive sleep apnea in adults with obesity is particularly relevant to coverage discussions.
Coverage still depends on the specific Medicare plan, indication, eligibility requirements, and applicable policy.
A prescription should therefore not be assumed to be covered simply because Zepbound has an FDA-approved indication.